Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV ovarian epithelial cancer or primary peritoneal cavity cancer meeting 1 of the following criteria: Progressive* or persistent* disease during or after primary chemotherapy Recurrent disease < 6 months after completion of primary therapy that had resulted in a complete response Persistent* or recurrent disease after second-line or additional therapies NOTE: *Progression or persistence can be based on serological (CA 125 > 100 U/mL OR 2 times baseline), radiographic (measurable or evaluable disease), or second-look surgical findings Tumor expressing NY-ESO-1 determined by IHC or RT-PCR HLA type expressing DPB*0401, DPB1*0201, DRB1*07 No CNS metastases PATIENT CHARACTERISTICS: Age 18 to 75 Performance status Karnofsky 70-100% Life expectancy More than 16 weeks Hematopoietic Not specified Hepatic Not specified Renal Creatinine ≤ 2.0 mg/dL Cardiovascular No congestive heart failure* No clinically significant hypotension* No symptoms of coronary artery disease* No cardiac arrhythmias on EKG requiring drug therapy* No history of cardiovascular disease* No other significant cardiovascular abnormalities* NOTE: *Patients with any of the above undergo a stress test and/or echocardiography before being determined ineligible for study participation Pulmonary FEV_1 ≥ 60% of predicted* DLCO ≥ 55%* NOTE: *Patients with clinically significant pulmonary dysfunction only Other Not pregnant or nursing Fertile patients must use effective contraception HIV negative No active infection No oral temperature > 38.2°C within the past 72 hours No systemic infection requiring chronic maintenance or suppressive therapy PRIOR CONCURRENT THERAPY: Biologic therapy No other concurrent immunotherapy (e.g., interleukins, interferons, vaccines, intravenous immunoglobulin, or expanded polyclonal tumor-infiltrating lymphocytes or lymphokine-activated killer cell therapy) Chemotherapy See Disease Characteristics At least 3 weeks since prior standard or experimental chemotherapy Endocrine therapy No concurrent systemic corticosteroids except for treatment-related toxicity Radiotherapy At least 3 weeks since prior radiotherapy Surgery See Disease Characteristics Other At least 3 weeks since prior immunosuppressive therapy More than 3 weeks since prior investigational drugs and recovered No other concurrent investigational agents No concurrent pentoxifylline